$FLKS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Salarius Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Salarius Pharmaceuticals, Inc.. Get notifications about new insider transactions in Salarius Pharmaceuticals, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 05 2021 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Grant | A | 0.57 | 9,563 | 5,422 | 26,286 | 16.7 K to 26.3 K (+57.18 %) |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | Burleson Tess | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | A | 0.74 | 275,000 | 203,500 | 275,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Option Exercise | A | 0.74 | 80,000 | 59,200 | 80,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | Lieber Jonathan I | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Dec 04 2020 | FLKS | Salarius Pharmaceu ... | Lammers Paul | Director | Option Exercise | A | 0.74 | 30,000 | 22,200 | 30,000 | |
Nov 05 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Grant | A | 0.56 | 4,879 | 2,737 | 86,425 | 81.5 K to 86.4 K (+5.98 %) |
Nov 05 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Grant | A | 0.56 | 4,723 | 2,650 | 16,723 | 12 K to 16.7 K (+39.36 %) |
Aug 24 2020 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Buy | P | 0.98 | 4,000 | 3,920 | 11,350 | 7.4 K to 11.4 K (+54.42 %) |
Aug 20 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Buy | P | 1.01 | 1,000 | 1,010 | 2,000 | 1,000 to 2 K (+100.00 %) |
Aug 20 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Buy | P | 1.01 | 1,000 | 1,010 | 1,000 | 0 to 1,000 |
Aug 18 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Buy | P | 1.00 | 5,000 | 5,000 | 12,000 | 7 K to 12 K (+71.43 %) |
Jul 16 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | A | 1.32 | 339,584 | 448,251 | 339,584 | |
Jul 16 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Option Exercise | A | 1.32 | 49,955 | 65,941 | 49,955 | |
Jul 16 2020 | FLKS | Salarius Pharmaceu ... | Lieber Jonathan I | Director | Option Exercise | A | 1.32 | 3,000 | 3,960 | 3,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | Northrup Jonathan P | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | Burleson Tess | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Option Exercise | A | 0.61 | 30,000 | 18,300 | 30,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | A | 0.61 | 60,000 | 36,600 | 60,000 | |
Mar 25 2020 | FLKS | Salarius Pharmaceu ... | Lammers Paul | Director | Option Exercise | A | 0.61 | 6,000 | 3,660 | 6,000 | |
Feb 20 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Buy | P | 0.95 | 2,000 | 1,900 | 7,000 | 5 K to 7 K (+40.00 %) |
Feb 18 2020 | FLKS | Salarius Pharmaceu ... | Jordan Scott | Chief Business Offi ... | Buy | P | 0.90 | 11,300 | 10,170 | 31,609 | 20.3 K to 31.6 K (+55.64 %) |
Feb 18 2020 | FLKS | Salarius Pharmaceu ... | Jordan Scott | Chief Business Offi ... | Buy | P | 0.90 | 11,300 | 10,170 | 31,609 | 20.3 K to 31.6 K (+55.64 %) |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Burleson Tess | Director | Option Exercise | P | 1.15 | 4,350 | 5,003 | 4,350 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Option Exercise | P | 1.15 | 8,700 | 10,005 | 8,700 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Option Exercise | P | 1.15 | 4,350 | 5,003 | 4,350 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Option Exercise | P | 1.15 | 8,700 | 10,005 | 8,700 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Rosenblum Mark J | Exec VP Finance, CF ... | Buy | P | 0.86 | 5,000 | 4,295 | 5,000 | 0 to 5 K |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | P | 1.15 | 2,175 | 2,501 | 2,175 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Northrup Jonathan P | Director | Option Exercise | P | 1.15 | 8,700 | 10,005 | 8,700 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | P | 1.15 | 2,175 | 2,501 | 2,175 | |
Feb 13 2020 | FLKS | Salarius Pharmaceu ... | Northrup Jonathan P | Director | Option Exercise | P | 1.15 | 8,700 | 10,005 | 8,700 | |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Buy | P | 1.15 | 8,700 | 10,005 | 8,700 | 0 to 8.7 K |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | Northrup Jonathan P | Director | Buy | P | 1.15 | 8,700 | 10,005 | 352,713 | 344 K to 352.7 K (+2.53 %) |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | Burleson Tess | Director | Buy | P | 1.15 | 4,350 | 5,003 | 4,350 | 0 to 4.4 K |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Buy | P | 1.15 | 4,350 | 5,003 | 7,350 | 3 K to 7.4 K (+145.00 %) |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Buy | P | 1.15 | 8,700 | 10,005 | 8,700 | 0 to 8.7 K |
Feb 12 2020 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Buy | P | 1.15 | 2,175 | 2,501 | 81,546 | 79.4 K to 81.5 K (+2.74 %) |
Nov 26 2019 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Buy | P | 3.59 | 3,000 | 10,770 | 6,000 | 3 K to 6 K (+100.00 %) |
Sep 13 2019 | FLKS | Salarius Pharmaceu ... | Arthur David J. | Chief Executive Off ... | Option Exercise | A | 8.00 | 30,000 | 240,000 | 30,000 | |
Sep 13 2019 | FLKS | Salarius Pharmaceu ... | Burleson Tess | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 13 2019 | FLKS | Salarius Pharmaceu ... | Northrup Jonathan P | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Jordan Scott | Chief Financial Off ... | Option Exercise | A | 8.00 | 10,000 | 80,000 | 10,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Lammers Paul | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Chuang Pao-Yu | Controller | Option Exercise | A | 8.00 | 10,000 | 80,000 | 10,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Jordan Scott | Chief Financial Off ... | Option Exercise | A | 8.00 | 10,000 | 80,000 | 10,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Lammers Paul | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | Chuang Pao-Yu | Controller | Option Exercise | A | 8.00 | 10,000 | 80,000 | 10,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | McCreedy Bruce J Jr. | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | McVicar William K. | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Sep 12 2019 | FLKS | Salarius Pharmaceu ... | HANISH ARNOLD C | Director | Option Exercise | A | 8.00 | 3,000 | 24,000 | 3,000 | |
Jan 10 2019 | FLKS | Flex Pharma, Inc. | Boston Foundation, Inc. | 10% Owner | Sell | S | 0.37 | 337,000 | 123,848 | 1,600,000 | 1.9 M to 1.6 M (-17.40 %) |
Jan 09 2019 | FLKS | Flex Pharma, Inc. | Boston Foundation, Inc. | 10% Owner | Sell | S | 0.40 | 263,000 | 104,306 | 1,937,000 | 2.2 M to 1.9 M (-11.95 %) |
Oct 18 2018 | FLKS | Flex Pharma, Inc. | Longwood Fund II, L.P. | 10% Owner | Sell | S | 0.92 | 3,212,861 | 2,941,053 | 0 | 3.2 M to 0 (-100.00 %) |
Oct 18 2018 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | 10% Owner | Sell | S | 0.92 | 3,212,861 | 2,941,053 | 0 | 3.2 M to 0 (-100.00 %) |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | RANDLE STUART A | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | KOZIN MARC D | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | Stacy Michelle | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | Tung Roger D | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | HUTT PETER BARTON | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jul 26 2018 | FLKS | Flex Pharma, Inc. | HUTT PETER BARTON | Director | Option Exercise | A | 0.82 | 10,000 | 8,200 | 10,000 | |
Jun 18 2018 | FLKS | Flex Pharma, Inc. | McVicar William K. | President and CEO | Option Exercise | A | 1.35 | 359,696 | 485,590 | 359,696 | |
Jan 19 2018 | FLKS | Flex Pharma, Inc. | McVicar William K. | President and CEO | Option Exercise | A | 3.98 | 250,000 | 995,000 | 250,000 | |
Jan 19 2018 | FLKS | Flex Pharma, Inc. | Woo Elizabeth | SVP, Investor Relat ... | Option Exercise | A | 3.98 | 50,000 | 199,000 | 50,000 | |
Jan 19 2018 | FLKS | Flex Pharma, Inc. | McCabe John P. | Chief Financial Off ... | Option Exercise | A | 3.98 | 100,000 | 398,000 | 100,000 | |
Jan 19 2018 | FLKS | Flex Pharma, Inc. | Wessel Thomas | Chief Medical Offic ... | Option Exercise | A | 3.98 | 100,000 | 398,000 | 100,000 | |
Nov 13 2017 | FLKS | Flex Pharma, Inc. | Tung Roger D | Director | Option Exercise | A | 3.47 | 20,000 | 69,400 | 20,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | PEREZ ROBERT J | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | Stacy Michelle | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | RANDLE STUART A | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | McVicar William K. | President and CEO | Option Exercise | A | 4.08 | 50,000 | 204,000 | 50,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | MacKinnon Roderick | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | KOZIN MARC D | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | HUTT PETER BARTON | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
Jul 27 2017 | FLKS | Flex Pharma, Inc. | CAPELLO JEFFREY D | Director | Option Exercise | A | 4.08 | 12,000 | 48,960 | 12,000 | |
May 30 2017 | FLKS | Flex Pharma, Inc. | McVicar William K. | President, R&D | Option Exercise | A | 3.37 | 200,000 | 674,000 | 200,000 | |
Jan 20 2017 | FLKS | Flex Pharma, Inc. | Woo Elizabeth | SVP, Investor Relat ... | Option Exercise | A | 4.58 | 47,000 | 215,260 | 47,000 | |
Jan 20 2017 | FLKS | Flex Pharma, Inc. | Wessel Thomas | Chief Medical Offic ... | Option Exercise | A | 4.58 | 85,000 | 389,300 | 85,000 | |
Jan 20 2017 | FLKS | Flex Pharma, Inc. | McCabe John P. | Chief Financial Off ... | Option Exercise | A | 4.58 | 67,000 | 306,860 | 67,000 | |
Jan 20 2017 | FLKS | Flex Pharma, Inc. | Lindemann Katharine | Chief Operating Off ... | Option Exercise | A | 4.58 | 77,000 | 352,660 | 77,000 | |
Jan 20 2017 | FLKS | Flex Pharma, Inc. | Hadfield Robert | General Counsel & S ... | Option Exercise | A | 4.58 | 57,000 | 261,060 | 57,000 | |
Nov 08 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 7.31 | 7,000 | 51,170 | 3,941,118 | 3.9 M to 3.9 M (+0.18 %) |
Nov 07 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 5.70 | 8,870 | 50,559 | 3,934,118 | 3.9 M to 3.9 M (+0.23 %) |
Nov 07 2016 | FLKS | Flex Pharma, Inc. | McCabe John P. | VP of Finance & Tre ... | Buy | P | 6.01 | 1,650 | 9,917 | 1,650 | 0 to 1.7 K |
Jul 12 2016 | FLKS | Flex Pharma, Inc. | SCULLEY JOHN | Director | Buy | P | 12.06 | 4,000 | 48,240 | 4,709 | 709 to 4.7 K (+564.17 %) |
Jul 12 2016 | FLKS | Flex Pharma, Inc. | SCULLEY JOHN | Director | Buy | P | 11.13 | 709 | 7,891 | 709 | 0 to 709 |
Jun 24 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.28 | 2,700 | 30,456 | 3,212,861 | 3.2 M to 3.2 M (+0.08 %) |
Jun 22 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.03 | 2,900 | 31,987 | 3,210,161 | 3.2 M to 3.2 M (+0.09 %) |
Jun 22 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.07 | 2,800 | 30,996 | 3,207,261 | 3.2 M to 3.2 M (+0.09 %) |
Jun 21 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.37 | 3,000 | 34,110 | 3,204,461 | 3.2 M to 3.2 M (+0.09 %) |
Jun 21 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.98 | 3,000 | 32,940 | 3,201,461 | 3.2 M to 3.2 M (+0.09 %) |
Jun 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.10 | 2,900 | 32,190 | 3,198,461 | 3.2 M to 3.2 M (+0.09 %) |
Jun 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.24 | 2,900 | 32,596 | 3,195,561 | 3.2 M to 3.2 M (+0.09 %) |
Jun 15 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.19 | 3,000 | 33,570 | 3,192,661 | 3.2 M to 3.2 M (+0.09 %) |
Jun 15 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.90 | 2,900 | 34,510 | 3,189,661 | 3.2 M to 3.2 M (+0.09 %) |
Jun 13 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.83 | 3,000 | 35,490 | 3,186,761 | 3.2 M to 3.2 M (+0.09 %) |
Jun 13 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.04 | 3,000 | 36,120 | 3,183,761 | 3.2 M to 3.2 M (+0.09 %) |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.24 | 2,900 | 35,496 | 3,180,761 | 3.2 M to 3.2 M (+0.09 %) |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.26 | 3,000 | 36,780 | 3,177,861 | 3.2 M to 3.2 M (+0.09 %) |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | Stacy Michelle | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | SCULLEY JOHN | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | RANDLE STUART A | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | PEREZ ROBERT J | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | MacKinnon Roderick | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | KOZIN MARC D | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | HUTT PETER BARTON | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 09 2016 | FLKS | Flex Pharma, Inc. | CAPELLO JEFFREY D | Director | Option Exercise | A | 12.21 | 10,000 | 122,100 | 10,000 | |
Jun 07 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.33 | 3,000 | 36,990 | 3,174,861 | 3.2 M to 3.2 M (+0.09 %) |
Jun 07 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.79 | 3,000 | 38,370 | 3,171,861 | 3.2 M to 3.2 M (+0.09 %) |
Jun 02 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 13.22 | 5,000 | 66,100 | 3,168,861 | 3.2 M to 3.2 M (+0.16 %) |
Jun 02 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.76 | 5,000 | 63,800 | 3,163,861 | 3.2 M to 3.2 M (+0.16 %) |
Jun 01 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.66 | 5,000 | 63,300 | 3,158,861 | 3.2 M to 3.2 M (+0.16 %) |
Jun 01 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.68 | 17,300 | 219,364 | 3,153,861 | 3.1 M to 3.2 M (+0.55 %) |
May 27 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.53 | 16,300 | 204,239 | 3,136,561 | 3.1 M to 3.1 M (+0.52 %) |
May 27 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 13.25 | 12,300 | 162,975 | 3,120,261 | 3.1 M to 3.1 M (+0.40 %) |
May 24 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.50 | 16,967 | 212,088 | 3,107,961 | 3.1 M to 3.1 M (+0.55 %) |
May 24 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 12.31 | 13,367 | 164,548 | 3,090,994 | 3.1 M to 3.1 M (+0.43 %) |
May 23 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.44 | 1,000 | 11,440 | 3,077,627 | 3.1 M to 3.1 M (+0.03 %) |
May 23 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.00 | 6,914 | 76,054 | 3,076,627 | 3.1 M to 3.1 M (+0.23 %) |
May 19 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.05 | 15,200 | 167,960 | 3,069,713 | 3.1 M to 3.1 M (+0.50 %) |
May 19 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.14 | 18,200 | 202,748 | 3,054,513 | 3 M to 3.1 M (+0.60 %) |
May 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.40 | 8,200 | 85,280 | 3,036,313 | 3 M to 3 M (+0.27 %) |
May 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.09 | 7,269 | 73,344 | 3,028,113 | 3 M to 3 M (+0.24 %) |
May 13 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 9.94 | 16,097 | 160,004 | 3,020,844 | 3 M to 3 M (+0.54 %) |
May 13 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.33 | 14,120 | 145,860 | 3,004,747 | 3 M to 3 M (+0.47 %) |
May 11 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.14 | 12,577 | 127,531 | 2,990,627 | 3 M to 3 M (+0.42 %) |
May 11 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 9.80 | 17,532 | 171,814 | 2,978,050 | 3 M to 3 M (+0.59 %) |
Mar 25 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.55 | 24,207 | 255,384 | 2,960,518 | 2.9 M to 3 M (+0.82 %) |
Mar 25 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.55 | 25,356 | 292,862 | 2,936,311 | 2.9 M to 2.9 M (+0.87 %) |
Mar 23 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.78 | 23,951 | 282,143 | 2,910,955 | 2.9 M to 2.9 M (+0.83 %) |
Mar 23 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.70 | 24,107 | 282,052 | 2,887,004 | 2.9 M to 2.9 M (+0.84 %) |
Mar 21 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 11.06 | 18,437 | 203,913 | 2,862,897 | 2.8 M to 2.9 M (+0.65 %) |
Mar 21 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.94 | 19,137 | 209,359 | 2,844,460 | 2.8 M to 2.8 M (+0.68 %) |
Mar 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 10.85 | 19,142 | 207,691 | 2,825,323 | 2.8 M to 2.8 M (+0.68 %) |
Mar 17 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 9.62 | 19,237 | 185,060 | 2,806,181 | 2.8 M to 2.8 M (+0.69 %) |
Mar 16 2016 | FLKS | Flex Pharma, Inc. | Stacy Michelle | Director | Buy | P | 9.63 | 2,585 | 24,894 | 2,585 | 0 to 2.6 K |
Mar 15 2016 | FLKS | Flex Pharma, Inc. | Longwood Fund II, L.P. | 10% Owner | Buy | P | 7.00 | 89,680 | 627,760 | 2,786,944 | 2.7 M to 2.8 M (+3.32 %) |
Mar 15 2016 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | President and CEO | Buy | P | 7.00 | 89,680 | 627,760 | 2,786,944 | 2.7 M to 2.8 M (+3.32 %) |
Mar 15 2016 | FLKS | Flex Pharma, Inc. | Wessel Thomas | Chief Medical Offic ... | Buy | P | 9.13 | 8,000 | 73,040 | 57,064 | 49.1 K to 57.1 K (+16.31 %) |
Mar 15 2016 | FLKS | Flex Pharma, Inc. | Wessel Thomas | Chief Medical Offic ... | Buy | P | 7.15 | 12,000 | 85,800 | 49,064 | 37.1 K to 49.1 K (+32.38 %) |